

## Lorvotuzumab

|           |   |
|-----------|---|
| Cat. No.: | HY-P99372   |
| CAS No.:  | 339306-30-8   |
| Target:   | ADC Antibody  |
| Pathway:  | Antibody-drug Conjugate/ADC Related   |
| Storage:  | Please store the product under the recommended conditions in the Certificate of Analysis. |

### BIOLOGICAL ACTIVITY

|                    |  |
|--------------------|--|
| <b>Description</b> | Lorvotuzumab (Anti-NCAM1/CD56 Reference Antibody (lorvotuzumab)) is a humanized monoclonal antibody that binds CD56 (NCAM1). Lorvotuzumab can be used to synthesize an ADC compound, Lorvotuzumab mertansine <sup>[1]</sup> .  |
| <b>In Vitro</b>    | Lorvotuzumab mertansine (IMGN901) is an ADC that links a potent anti-mitotic (DM1) via a disulfide linker to CD56 targeting antibodies (Lorvotuzumab). Lorvotuzumab mertansine against Wilms tumor, rhabdomyosarcoma, and neuroblastoma <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only. |

### REFERENCES

[1]. James I Geller, et al. ADVL1522: A phase 2 study of lorvotuzumab mertansine (IMGN901) in children with relapsed or refractory wilms tumor, rhabdomyosarcoma, neuroblastoma, pleuropulmonary blastoma, malignant peripheral nerve sheath tumor, or synovial sarcoma-A Children's Oncology Group study. Cancer. 2020 Dec 15;126(24):5303-5310.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA